fda warning letters glp-1 compounders september 2025 Issues to Telehealth Companies for False Clai FDA Moves to Restrict Mass-Marketed

In the research literature, CJC-1295 without DAC is described as a molecule that stimulates the GHRH receptor in the pituitary and triggers a short, pulsatile GH peak

Pregnancy and breastfeeding are stopping points: concentrated methyl-donor combinations are not well studied in pregnancy, and guidance is to avoid Lipo-C unless a clinician judges maternal benefit to outweigh theoretical risk under obstetric supervision

New England Journal of Medicine , 383 (11), 1000-1002

Up-titration can be slowed to limit severity and frequency of side effects

The table reveals why researchers find this combination theoretically interesting